| Literature DB >> 35326965 |
Sonia Sifuentes-Franco1,2, Dellaneira Carolina Sánchez-Macías3, Sandra Carrillo-Ibarra3, Juan José Rivera-Valdés4, Laura Y Zuñiga2, Virginia Aleyda Sánchez-López5.
Abstract
With the appearance of new viruses and infectious diseases (ID) such as COVID-19 in 2019, as well as the lack of specific pharmacological tools for the management of patients with severe complications or comorbidities, it is important to search for adjuvant treatments that help improve the prognosis of infectious disease patients. It is also important that these treatments limit the oxidative and hyperinflammatory damage caused as a response to pathogenic agents, since, in some cases, an inflammatory syndrome may develop that worsens the patient's prognosis. The potential benefits of complementary nutrients and dietary interventions in the treatment of pathological processes in which oxidative stress and inflammation play a fundamental role have been widely evaluated. Coenzyme Q10 (CoQ10) is a supplement that has been shown to protect cells and be effective in cardiovascular diseases and obesity. Additionally, some studies have proposed it as a possible adjuvant treatment in viral infections. Preclinical and clinical studies have shown that CoQ10 has anti-inflammatory and antioxidant effects, and effects on mitochondrial dysfunction, which have been linked to the inflammatory response.Entities:
Keywords: CoQ10; antioxidant; infectious disease; inflammation and immunomodulator; ubiquinone
Year: 2022 PMID: 35326965 PMCID: PMC8953254 DOI: 10.3390/healthcare10030487
Source DB: PubMed Journal: Healthcare (Basel) ISSN: 2227-9032
Figure 1Antioxidant and anti-inflammatory functions of CoQ10. During an infectious process, the cells of the immune response produce cytokines and reactive oxygen species (ROS) as a mechanism to combat a pathogen, these ROS can produce lipoperoxidation, which can be inhibited by the direct antioxidant effect of CoQ10. The main function of CoQ10 in the mitochondria is to transfer electrons to complex III (CIII). By transferring two electrons to Complex III, the reduced form of CoQ10 (ubiquinol) is oxidized to ubiquinone. The ubiquinol pool can be restored by accepting electrons from members of the electron transport chain (CI and CII). The anti-inflammatory effects of CoQ10 may be linked to the regulation of IL-1, IL-6, CRP and TNF-α gene expression through the NF-kB pathway. Figure was created with BioRender software, (Toronto, ON, Canada) ©biorender.com.
Antioxidants and anti-inflammatory effects of CoQ10 in infectious diseases: human clinical trials.
| Authors | Study Design | Sample Size | Objective | Results |
|---|---|---|---|---|
| Soltani et al. [ | Randomized, controlled trial. Follow-up: 7 days-oral administration of 200 mg daily of CoQ10 |
57 Sepsis patients (randomized) 40 Sepsis patients (completed trial) | Evaluate the effects of CoQ10 supplementation in patients with early sepsis to determine its effects on markers of inflammation and oxidative stress, as well as the clinical impact |
CoQ10 group, TNF-α and MDA levels decrease CoQ10 administration improves patient survival |
| Dominno et al. [ | Randomized, double-blind, pilot trial | 38 patients with severe sepsis | To evaluate the effect of parenteral administration of ubiquinol in patients with severe sepsis on markers of inflammation and markers of vascular endothelial injury. |
IL-6 levels at 12, 24, 48 and 72 h were higher in patients who received ubiquinol compared to those who received placebo In the levels of cytochrome C there was also no difference between the groups after the administration of CoQ10 There was no difference in hospital mortality between patients who received ubiquinol versus placebo |
| Yousefi et al. [ | Randomized, double blind, placebo controlled, parallel group clinical trial. Follow-up: 3 months-oral administration of 200 mg daily of CoQ10 | 73 patients with HIV infected | To determine the effect on the effects of CoQ10 on CD4 count in HIV infected patients. | In both study groups the mean TCD4+ cell count increased significantly at the end of treatment. there were no changes in markers of liver and kidney function |
| De Luca et al. [ | Two clinical trials were carried out: Double-blind placebo-controlled randomized clinical trial on adult patients with human papillomavirus (HPV) (verruca vulgaris or plantaris) Follow-up: 180 days of nutraceutical or placebo administration Open-label clinical trial on patients affected with herpes disease relapses Follow-up: 90 days of nutraceutical or acyclovir administration |
68 patients with relapsing HPV skin warts treated with cryotherapy 89 patients affected with herpes disease relapses | To assess the effect of nutritional therapies with coenzyme Q10, RRR-a-tocopherol, selenium aspartate, and L-methionine associated with established therapies in patients with chronic mucocutaneous infections. |
In both trials, the nutraceutical induced significantly faster healing with reduced incidence of relapses as compared to control groups. The group receiving nutraceutical therapy increases GSH levels at the end of the study The combination of nutraceuticals with conventional treatment with acyclovir improved the results with a very pronounced decrease in blood viral load compared to the control treatment group Increased antiviral cytokine and peroxynitrite plasma levels. Plasma antioxidant capacity was higher in the experimental versus control groups. |
| Shao et al. [ | Randomized, double blind. Three study groups: CQ10 group, trimetazidine group and CQ10 + trimetazidine group Follow-up: two weeks in patients with acute viral myocarditis | CQ10 group ( | To evaluate the effect of CQ10 and trimetazidine as monotherapy and in combination for the treatment of acute viral myocarditis. | Inflammation and oxidative markers and myocardial enzymes decreased in all group, but the combination group showed the most powerful effect |
| Rangel-Guerra et al. [ | Case report | Case report (1) | Report the case of a patient with anti-NMDAR | A significant improvement is observed in the patient after the administration of CoQ10, however the results are not conclusive, the effects could be due to the late response to immunotherapy |